BR122013002187A2 - peptídeo e composição farmacêutica compreendendo o mesmo - Google Patents

peptídeo e composição farmacêutica compreendendo o mesmo

Info

Publication number
BR122013002187A2
BR122013002187A2 BR122013002187A BR122013002187A BR122013002187A2 BR 122013002187 A2 BR122013002187 A2 BR 122013002187A2 BR 122013002187 A BR122013002187 A BR 122013002187A BR 122013002187 A BR122013002187 A BR 122013002187A BR 122013002187 A2 BR122013002187 A2 BR 122013002187A2
Authority
BR
Brazil
Prior art keywords
ang
pharmaceutical composition
peptide
receptor
agonist
Prior art date
Application number
BR122013002187A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas Walther
Wolfgang Kuebler
Original Assignee
Charite Universitätsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitätsmedizin Berlin filed Critical Charite Universitätsmedizin Berlin
Publication of BR122013002187A2 publication Critical patent/BR122013002187A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR122013002187A 2008-09-12 2009-09-11 peptídeo e composição farmacêutica compreendendo o mesmo BR122013002187A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08016142A EP2163259B1 (en) 2008-09-12 2008-09-12 Use of an Ang-(1-7) receptor agonist in acute lung injury
BRPI0918443A BRPI0918443A2 (pt) 2008-09-12 2009-09-11 uso de uma agonista receptor de ang-(1-7) em lesão pulmonar aguda
PCT/EP2009/006619 WO2010028845A2 (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury

Publications (1)

Publication Number Publication Date
BR122013002187A2 true BR122013002187A2 (pt) 2016-04-05

Family

ID=40430691

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122013002187A BR122013002187A2 (pt) 2008-09-12 2009-09-11 peptídeo e composição farmacêutica compreendendo o mesmo
BRPI0918443A BRPI0918443A2 (pt) 2008-09-12 2009-09-11 uso de uma agonista receptor de ang-(1-7) em lesão pulmonar aguda

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0918443A BRPI0918443A2 (pt) 2008-09-12 2009-09-11 uso de uma agonista receptor de ang-(1-7) em lesão pulmonar aguda

Country Status (9)

Country Link
US (4) US20110281805A1 (cg-RX-API-DMAC7.html)
EP (2) EP2163259B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012502071A (cg-RX-API-DMAC7.html)
KR (1) KR20110074978A (cg-RX-API-DMAC7.html)
CN (2) CN103263661A (cg-RX-API-DMAC7.html)
BR (2) BR122013002187A2 (cg-RX-API-DMAC7.html)
CA (1) CA2736922C (cg-RX-API-DMAC7.html)
ES (1) ES2393455T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010028845A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
CN102532265A (zh) * 2011-12-29 2012-07-04 中国人民解放军第四军医大学 一种短肽、其异构体及其应用
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
CA2884792A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CN105636645A (zh) * 2013-04-19 2016-06-01 爱荷华大学研究基金会 在肌萎缩症中的血管紧张素
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
WO2015054005A1 (en) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
RU2016152088A (ru) * 2014-07-17 2018-08-21 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата
CN106535920B (zh) 2014-07-21 2020-10-30 代表亚利桑那大学的亚利桑那校董会 Ang-(1-7)衍生物寡肽及其使用和生产方法
US10183055B2 (en) * 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
JP7010698B2 (ja) * 2015-04-08 2022-01-26 コーニンクレッカ フィリップス エヌ ヴェ 急性呼吸促迫症候群(ards)のリスクスコアによって導かれる換気治療推薦のためのツール
WO2018129511A2 (en) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
CN112316107B (zh) * 2019-07-17 2023-01-06 首都医科大学附属北京妇产医院 血管紧张素(1-7)在胰腺疾病中的应用
WO2021183863A1 (en) * 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
WO2022094025A1 (en) * 2020-10-30 2022-05-05 Gere Dizerega Angiotensin-1-7 for the treatment of covid-19
US12343331B2 (en) 2021-01-28 2025-07-01 Capacity Bio, Inc. Methods and agents that stimulate mitochondrial turnover for treating disease
EP4085921A1 (en) 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases
CN117147877A (zh) * 2023-08-30 2023-12-01 重庆医科大学附属儿童医院 Ang1-7作为生物标志物在预测、诊断儿童脓毒症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
BRPI0503122A (pt) 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas

Also Published As

Publication number Publication date
JP5881122B2 (ja) 2016-03-09
BRPI0918443A2 (pt) 2015-11-24
CA2736922C (en) 2014-08-19
US20120321701A1 (en) 2012-12-20
CA2736922A1 (en) 2010-03-18
WO2010028845A3 (en) 2010-06-10
CN102164614A (zh) 2011-08-24
JP2012502071A (ja) 2012-01-26
CN102164614B (zh) 2014-03-26
KR20110074978A (ko) 2011-07-05
WO2010028845A2 (en) 2010-03-18
US8383772B2 (en) 2013-02-26
HK1161100A1 (en) 2012-08-24
EP2163259A1 (en) 2010-03-17
EP2163259B1 (en) 2012-06-13
CN103263661A (zh) 2013-08-28
US20110281805A1 (en) 2011-11-17
US20160051621A1 (en) 2016-02-25
ES2393455T3 (es) 2012-12-21
US20140073760A1 (en) 2014-03-13
JP2014074048A (ja) 2014-04-24
EP2341938A2 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
CA2736922C (en) Use of an ang-(1-7) receptor agonist in acute lung injury
AU2014364528B2 (en) Angiotensin ll alone or in combination for the treatment of hypotension
Champion et al. Nociceptin, an endogenous ligand for the ORL1 receptor, decreases cardiac output and total peripheral resistance in the rat
Corboz et al. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung
TWI754225B (zh) 治療低血壓之方法
Ikeda et al. Biased agonism of the angiotensin II type I receptor a potential strategy for the treatment of acute heart failure
Hollenberg et al. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats
Lange et al. Vasopressin vs. terlipressinin the treatmentof cardiovascular failure in sepsis
JP2019508378A (ja) 昇圧薬の投与方法
JP2019501201A (ja) アンジオテンシンiiの投与方法
Rosseel et al. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?
Ullman et al. Hemodynamic effects of vasopressin antagonism and angiotensin I converting enzyme inhibition during halothane anesthesia in sheep
HK1161100B (en) Use of an ang-(1-7) receptor agonist in acute lung injury
Phuong et al. Comparative effects of angiotensin II and angiotensin-(4-8) on blood pressure and ANP secretion in rats
Kunstyr et al. A retrospective analysis of Terlipressin infusion in patients with refractory hypotension after cardiac surgery
Yokota et al. Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension
Koch et al. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model
HK40050536A (en) Angiotensin ii alone or in combination for the treatment of hypotension
Eszlári Cardiac and peripheral hemodynamic effects of selective endothelin-A receptor antagonism
Vajda Microcirculatory heterogeneity during compromised flow conditions in the intestine

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2467 DE 17/04/2018.